Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide Diskus
NCT01856621 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48
Last updated 2014-01-03
Summary
The purpose of this study is to compare the test product Salmeterol/fluticasone Easyhaler with the reference product Seretide Diskus in terms of drug absorbed in the bloodstream.
Conditions
Interventions
- DRUG
-
Seretide Diskus and charcoal
2 inhalations as a single dose
- DRUG
-
Seretide Diskus
2 inhalations as a single dose
- DRUG
-
SF Easyhaler and charcoal
2 inhalations as a single dose
- DRUG
-
SF Easyhaler
2 inhalations as a single dose
Sponsors & Collaborators
-
Orion Corporation, Orion Pharma
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-05-31
- Primary Completion
- 2013-09-30
- Completion
- 2013-09-30
Countries
- Finland
Study Locations
More Related Trials
-
Phase I Pharmacokinetic Study (SALBLOCK)
NCT01564199 ·Status: COMPLETED ·Phase: PHASE1
-
Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics
NCT00364442 ·Status: COMPLETED ·Phase: PHASE1
-
A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade
NCT04124094 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers
NCT01181063 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma
NCT04665895 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Compare Fluticasone Propionate 100mcg/Salmeterol 50 mcg Inhalation Powder to Advair Discus 100/50
NCT03562923 ·Status: UNKNOWN ·Phase: PHASE3
-
Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma
NCT05664061 ·Status: UNKNOWN ·Phase: PHASE3
-
Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).
NCT00404261 ·Status: COMPLETED ·Phase: PHASE4
-
Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate
NCT02232087 ·Status: COMPLETED ·Phase: PHASE1
-
To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product
NCT02308098 ·Status: COMPLETED ·Phase: PHASE3
-
ROTAHALER Device Optimization Study
NCT01890863 ·Status: COMPLETED ·Phase: PHASE1
-
Airway Clearance Study
NCT00379028 ·Status: COMPLETED ·Phase: PHASE4
-
A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC)
NCT03894280 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs
NCT02215122 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhaler
NCT00868426 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
NCT05697003 ·Status: UNKNOWN ·Phase: PHASE1
-
An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy Volunteers
NCT01449799 ·Status: COMPLETED ·Phase: PHASE1
-
Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD
NCT03755544 ·Status: COMPLETED
-
A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® Inhaler
NCT02218762 ·Status: WITHDRAWN ·Phase: PHASE1
-
Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
NCT05085587 ·Status: UNKNOWN ·Phase: PHASE1
-
Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients
NCT01795664 ·Status: COMPLETED ·Phase: PHASE3
-
Influence Of Different Airflow Resistances On Drug Effect Of 50μg Salmeterol And 6 μg Formoterol
NCT00327353 ·Status: COMPLETED ·Phase: PHASE4
-
A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers
NCT04564456 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®
NCT00542880 ·Status: COMPLETED ·Phase: PHASE4
-
Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients
NCT00830102 ·Status: COMPLETED ·Phase: PHASE2